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Abstract
Background: Molecular studies of the human disease transcriptome typically involve a search for genes whose expression is
significantly dysregulated in sick individuals compared to healthy controls. Recent studies have found that only a small
number of the genes in human disease-related pathways show consistent dysregulation in sick individuals. However, those
studies found that some pathway genes are affected in most sick individuals, but genes can differ among individuals. While
a pathway is usually defined as a set of genes known to share a specific function, pathway boundaries are frequently
difficult to assign, and methods that rely on such definition cannot discover novel pathways. Protein interaction networks
can potentially be used to overcome these problems.
Methodology/Principal Findings: We present DEGAS (DysrEgulated Gene set Analysis via Subnetworks), a method for
identifying connected gene subnetworks significantly enriched for genes that are dysregulated in specimens of a disease.
We applied DEGAS to seven human diseases and obtained statistically significant results that appear to home in on compact
pathways enriched with hallmarks of the diseases. In Parkinson’s disease, we provide novel evidence for involvement of
mRNA splicing, cell proliferation, and the 14-3-3 complex in the disease progression. DEGAS is available as part of the
MATISSE software package (http://acgt.cs.tau.ac.il/matisse).
Conclusions/Significance: The subnetworks identified by DEGAS can provide a signature of the disease potentially useful
for diagnosis, pinpoint possible pathways affected by the disease, and suggest targets for drug intervention.
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Introduction
Systems biology has the potential to revolutionize the diagnosis
and treatment of complex disease by offering a comprehensive
view of the molecular mechanisms underlying their pathology. To
achieve these goals, biologists need computational methods that
extract mechanistic understanding from the masses of available
data. To date, the main sources of such data are microarray
measurements of genome-wide expression profiles, with over
400,000 profiles stored in GEO [1] alone as of April 2010. A wide
variety of approaches for elucidating molecular mechanisms from
expression data have been suggested [2,3]. However, most of these
methods are effective only when using expression profiles obtained
under diverse conditions and perturbations, while the bulk of data
currently available from clinical studies are expression profiles of
groups of diseased individuals and matched controls. These data
are useful for characterizing the molecular signature of a disease
for diagnostic and prognostic purposes [4,5]. However, using these
expression profiles to obtain a better understanding for the
pathogenesis is significantly more difficult. The standard methods
applied to these data identify the genes that best predict the
pathological status of the samples. While these methods are
successful in identifying potent signatures for classification
purposes, the mechanistic insights that can be obtained from
examining the gene lists they produce are frequently limited [6].
Standard statistical tests, as well as the vast majority of more
sophisticated methods utilizing diverse genomic data, look for
genes whose expression is significantly and robustly different in the
case and in the control cohorts. Several recent comprehensive
studies, mostly in the context of cancer, have found that few genes
meet these criteria. Yet, many of the affected individuals were
found to carry dysregulated genes that belong to specific disease-
related pathways [7,8,9,10]. In order to identify such pathways,
these studies utilized a fixed collection of gene lists based on
current biological knowledge. While several computational
methods have been developed for quantifying the changes in the
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knowledge of the true pathways is very incomplete, and pathway
boundaries are often difficult to assign. In addition, frequently,
only part of the pathway is altered during disease. Therefore, it is
more desirable to be able to identify disease-related pathways de
novo, without assuming prior knowledge of the pathways. The use
of gene networks for finding disease-related pathways that form
connected subnetwork has been suggested for this problem
[19,20]. The drawback of this approach is that it can only use
genes that are connected to other pathway members through
physical interactions. However, the appeal of using network
information increases as the quality and scale of experimental data
on such interaction networks improve [21].
Several approaches for integrating microarray measurements
with network knowledge were described in the literature. Some
(including us) proposed computational methods for detection of
subnetworks that show correlated expression [22,23,24,25]. A
successful method for detection of ‘active subnetworks’ was
proposed by Ideker et al. and extended by other groups
[26,27,28,29,30]. These methods are based on assigning a
significance score to every gene in every sample and looking for
subnetworks with statistically significant combined scores. Breitling
et al. proposed a simple method named GiGA which receives a list
of genes ordered by their differential expression significance and
extracts subnetworks corresponding to the most differentially
expressed genes [31]. Other methods used differential expression
scores assigned to individual genes and look for subnetworks with
high aggregate scores [32,33]. Other tools used network and
expression information together for classification purposes [19,20].
Finally, others used networks to identify novel disease-related
genes based on their proximity to known disease related genes
[34,35,36,37,38].
Methods based on correlated expression patterns do not use the
sample labels, and thus their applicability for case-control data is
limited, as correlation between transcript levels can stem from
numerous confounding factors not directly related to the disease
(e.g., age or gender). The extant methods that do use the sample
labels rely on the assumption that the same genes in the pathway
are differentially expressed in all the samples (an exception is
jActiveModules, which can identify a subset of the samples in
which the subnetwork is active [26]). This assumption may hold in
simple organisms (e.g., yeast or bacteria) or in cell line studies.
However, in human disease studies, the samples are expected to
exhibit intrinsic differences due to genetic background, environ-
mental effects, tissue heterogeneity, disease grade and other
confounding factors. Thus, improved methods that can account
for this variability and recover focused disease-affected pathways
are needed.
Here we describe DEGAS (DysrEgulated Gene set Analysis via
Subnetworks), a new method for analysis of clinical gene
expression samples in the context of interaction networks, which
avoids the above assumption. Given a set of expression profiles
labeled as cases and another set of controls, DEGAS aims to detect
subnetworks in which multiple genes are dysregulated in the cases,
while allowing for distinct affected gene sets in each case profile.
We call such modules dysregulated pathways (DPs). Specifically, for
each gene, we use the distribution of values in the controls in order
to determine in which cases that gene is dysregulated. We then
look for minimal connected subnetworks of the given protein
interaction network in which the number of dysregulated genes in
each case exceeds a given threshold. By comparing to statistics of
randomized networks, we can select a meaningful value for this
threshold and identify statistically significant DPs. As finding DPs
is computationally hard, we propose heuristics and algorithms with
provable approximation ratios and study their performance. Our
approach has several important advantages over the existing
methods: (a) the dysregulated genes in a DP can vary between
patients; (b) the method is robust to outliers (i.e., patients with
unusual profiles); (c) the DPs can contain relevant genes based on
their interaction pattern, even if they are not dysregulated; (d) it
has a limited number of parameters, all of which have an intuitive
biological interpretation; (e) while not guaranteeing optimality, the
algorithmic core of the method has a provable performance
guarantee.
In order to test the performance of our method, we collected 13
case-control gene expression datasets for seven diseases, and tested
the ability of DEGAS and other methods [26,31] to recover a
pathway corresponding to the relevant disease pathway in the
KEGG database [39]. Comparing our method to existing
alternatives [26,31] we find that DEGAS can identify more
specific and focused subnetworks which capture a significant
fraction of the known disease-related pathways. Using a dataset of
gene expression in tongue squamous cell carcinoma we show how
DEGAS can identify the known hallmarks of a well studied
disease. We then focus on Parkinson’s Disease (PD), which is
relatively poorly understood on the molecular level, and show how
DEGAS can suggest mechanisms that are affected in PD brain,
some of which have support in other existing data. We obtain
consistent results in two different PD datasets. Mainly, our results
point to a previously unrecognized pathway-level dysregulation of
mRNA splicing in PD patients.
A preliminary version of this paper appeared in [40]. This
version differs in the exact problem formulation, the algorithmic
details, and in the implementation. Moreover, the data analysis
has been completely revised and this version contributes novel
biological insights derived from DEGAS.
An implementation of DEGAS with a full graphical user
interface for parameter specification and network visualization is
available as part of the MATISSE network analysis software at
http://acgt.cs.tau.ac.il/matisse.
Results
A framework for detection of pathways dysregulated in
human disease
In this section we describe the theoretical foundations of our
methodology (Figure 1), which are detailed in the Methods
section and in the Text S1. The input to our method consists of a
network, which is an undirected and unweighted graph, and a
collection of gene expression profiles, divided into ‘control’ and
‘case’ cohorts (Figure 1A). Each expression profile consists of the
expression levels of some of the nodes in the network in one
individual (some genes may not have expression data, e.g., because
they were absent from the microarray). Our basic formulation
defines a dysregulated pathway as the smallest connected subgraph
in the network in which a specific number of genes are
dysregulated for each case when compared to controls. We look
for the smallest possible network, as it corresponds to the most
focused ‘explanation’ of the disease in terms of gene expression. In
other words, we are seeking clusters of gene expression
dysregulation events in the network. See Methods for formal
definitions.
In the first step, we identify, in each case profile, the set of genes
that are dysregulated when compared to controls (Figure 1B, see
Methods). Our goal is then to identify the smallest subgraph that
contains (covers) at least k genes from each of those sets, except for
up to l outlier sets, from which fewer genes can be present
(Figure 1C). Our method thus has two main parameters k - the
DEGAS
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the number of allowed outliers (cases excluded from the analysis).
Our initial results have shown that, in this basic formulation,
small DPs frequently correspond to sparse subnetworks that were
frequently not biologically relevant (results not shown). We
adjusted our problem formulation accordingly, and focused on
identifying DPs that are not only small, but also have the smallest
possible radius – i.e., all the nodes in a DP are within a short
distance from some root node (Figure 2, see Methods).
The DEGAS algorithm
The problem of identifying dysregulated pathways is related to
the set cover problem, a classical problem known to be
computationally hard. We have developed and compared three
different algorithms for solving this problem. Two of these
algorithms can identify pathways that are within a certain margin
of error from the optimal solution, while the third can deliver
arbitrarily large pathways in some specific problem instances.
However, we found that, on biological data, the third algorithm
augmented with a few heuristics tends to identify DPs that are
significantly smaller (and therefore more biologically plausible)
than the former two algorithms (see Methods for details). We
therefore used this algorithm (which we refer to as DEGAS) in the
rest of this paper.
DEGAS is described in detail in the Methods section.
Abstractly, DEGAS consists of two phases. First, we identify
nodes that could be potentially good starting points for the
algorithm – these are nodes in the vicinity of which a possible
solution can be found. The r- neighborhood of node v is the set of
all the nodes that can be reached from v by a path that contains #r
edges. We test all the nodes in the graph and find rmin – the smallest
r for which some node contains a proper DP in its r –
neighborhood. Only those nodes for which a proper DP is found
in their rmin-neighborhood are considered as starting points in the
second phase, in which for each such root node we perform a
greedy search that attempts to find the smallest DP in the rmin-
neighborhood. Each search starts with a partial DP that contains
only the root and iteratively expands it. For a partial DP, call the
cases for which less than k genes are in the DP the uncovered cases. In
every iteration, DEGAS searches the nodes neighboring the DP
for a node that covers the largest number of uncovered cases and
adds this node to the DP. The greedy search stops when the
number of uncovered cases is at most l. The smallest DP(s)
identified over all the searches are then returned.
Since the outliers are not specified in advance, the search
algorithm may add to the DP surplus nodes that are covering cases
which are eventually discarded. We attempt to deal with this
problem by running the search algorithm twice – the set of outliers
Figure 1. A dysregulated pathway (DP). (A) The input to our method consists of expression data of case and control cohorts and a protein
interaction network. (B) The expression data are converted into a binary genes over cases matrix in which ‘‘1’’ appears in position (i,j) if gene i is
dysregulated in case j (relative to the expression levels of i in the control cohort). (C) The interaction network: The vector next to each protein is the
dysregulation status (0 or 1) of that gene in each case. A DP is a minimal subnetwork in which at least k genes are dysregulated in all but l cases. In
the shown example, k=2and l=1. In the circled subnetwork, two out of the three genes are dysregulated in the first and the third case (the second
case is the outlier). (D) An alternative representation of the data in C, as a bipartite graph. Genes are on the left and cases are on the right. The blue
edges are protein interactions and the gray edges connect the genes with cases in which they are dysregulated.
doi:10.1371/journal.pone.0013367.g001
DEGAS
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which no further outliers are allowed (see Methods for details).
Assessment of DP significance
One of the main issues determining the performance of DEGAS
is the setting of the parameters. The l parameter (the number of
outlier cases) can be set based on the a priori assessment of the
homogeneity of the case cohort in the study. In all the analyses
described here, we set l to 20% of the cases in the dataset. The
setting of the k parameter (the number of genes affected in each
case) is more difficult, since in the vast majority of human diseases,
the number of critical dysregulation events in the affected pathway
is unknown. Recall that our goal is to identify significant
concentration of dysregulation events in a single pathway. We
therefore decided that the best value for the k parameter will be
the one for which the size of the smallest DP found is significantly
smaller than that obtained in random networks. For each tested k
value we computed the sizes of the DP found in the network, and
used the distribution of the sizes of the DPs found in randomly
permuted networks, to assign an empirical p-value, which reflects
the fraction of random networks in which an equal-sized or smaller
DP can be found. The parameter k yielding the most significant p-
value is then reported.
A compendium of disease pathways
A rigorous assessment of the performance of DEGAS required
gene expression datasets consisting of cases and controls for a
specific disease, as well as sets of genes known to be related to the
disease. To this end, we assembled a collection of 13 datasets
consisting of case and control gene expression profiles, for which a
corresponding pathway was present in the KEGG database as of
July 2009 [41,42,43,44,45,46,47,48,49] (Table 1). We used only
datasets in which a healthy tissue was compared to the disease
tissue (i.e., datasets with multiple prognosis-based cohorts were
excluded). For uniformity, we only used datasets that employed the
relatively widely used Affymetrix microarrays from the HG-U133
series. For each dataset, we used DEGAS to identify DPs up-
regulated in cases compared to controls (‘‘UP’’), down-regulated in
cases compared to controls (‘‘DOWN’’) or differentially expressed
between the two cohorts (‘‘DIFF’’).
We first evaluated the performance of different variants of our
algorithm and found that DEGAS usually identified the smallest
pathways (Text S1 and Figure S1).
We next compared the results of DEGAS to those of three other
methods for identifying pathways using network and expression
data, jActiveModules [26], GiGA [31] and BioNet (implementing
the algorithm described in [32]), and to t-test, which identifies sets
of differentially expressed genes. jActiveModules and BioNet
assign a differential expression score to every gene in every case,
and then seek subnetworks with high aggregate scores [26].
jActiveModules selects a subset of samples for each module to
maximize the score. GiGA first sorts all the nodes based on their
differential expression score (e.g., the t-test p-value). Starting from
the top ranked node, it iteratively adds the highest ranking node
that is adjacent to at least one previously selected node. As GiGA
requires the number of genes in the module to be set in advance,
we set the size of GiGA modules to be the same as the best
DEGAS module. When using t-test we selected either all the
differentially expressed genes at FDR,0.05 (‘‘t-test all’’), or the
same number of top differentially expressed genes as identified
using DEGAS (‘‘t-test top’’). For each dataset we used each
method to identify a module (or a set of genes for t-test) that is up-
regulated, down-regulated or differentially expressed in the cases
compared to the controls.
We first compared the significance of the overlap between the
obtained module and the KEGG pathway using the hypergeo-
metric test. For each method, the most significant p-value obtained
(inspecting up-regulation, down-regulation or differential expres-
sion) is shown in Figure 3A. For three datasets (SLE, LESNICK-
PD and ASTHMA) we found that all the methods failed to identify
Figure 2. DEGAS outline. All the nodes in the network are tested as potential root nodes for a minimal radius DP. For each node, we efficiently
compute the smallest radius for which some DP exists in the r-neighborhood of the node. All the nodes for which this radius is minimal are used to
construct DP using the ExpandingGreedy heuristic (see Methods). The smallest DPs identified over all the tested roots are reported.
doi:10.1371/journal.pone.0013367.g002
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later, in at least one of those cases (LESNICK-PD) we identify
multiple potential biological insights from the DEGAS module). In
the other datasets, jActiveModules performed best, outperforming
the other methods in four cases. However, we found that the
modules identified by jActiveModules were very large (Figure 3B),
typically an order of magnitude larger than those of DEGAS,
making them very difficult to interpret and use for derivation of
biologically or clinically relevant insights. The hypergeometric test
is known to be biased for larger modules, as they can give rise to
much more significant overlaps. For example, in the MOR-
AN_PD dataset, the most significant jActiveModules module
contained 756 genes, only 31 of which (4%) were a part of the PD
pathway in KEGG. The DEGAS module in this case contained
only 67 genes, 9% of which were known to be PD-related. Indeed,
we found that when comparing the fraction of the module that
corresponded to the known KEGG pathway, DEGAS consistently
outperformed jActiveModules, and performed better than all the
competing methods in six datasets (Figure 3C). We thus conclude
that DEGAS is capable of identifying small and focused modules
that are more specific with respect to disease-related genes than
those of jActiveModules, GiGA, BioNet or t-test.
Pathway up-regulated in tongue carcinoma captures
hallmarks of cancer
We now focus on a 51-gene subnetwork identified by DEGAS
as up-regulated in oral tongue squamous cell carcinoma
(OTSCC), using a gene expression dataset due to Ye et al. [45]
(YE-OTSCC-UP, k=30 and p,0.005, Figure 4). As expected
from a pathway up-regulated in quickly proliferating cells, this
pathway is significantly enriched with genes annotated with ‘‘cell
cycle’’ (p=6.72?10
214) and ‘‘regulation of cell cycle’’
(p=6.57?10
28) in GO. The most enriched KEGG annotations
in this pathway are ‘‘Cell cycle’’ (p=2.33 ?10
29) and ‘‘Pathways in
cancer’’ (p=1.6?10
28). In addition, it contains several members of
key canonical oncogenic pathways (taken from MSigDB and




25). Despite the fact that this pathway was
discovered without using any genetic data, it was enriched with
genes frequently mutated in cancer (taken from Cancer Gene
Census [50], p=1.34?10
24). Finally, the pathway was also
enriched with genes whose disruption causes tumorgenesis in
mice (taken from Mammalian Pheotype Ontology [51]). Taken
together, these enrichments show how DEGAS can identify a
focused subnetwork that contains the hallmarks of oncogenesis
using a protein interaction network coupled with gene expression
data comparing tumors to matching healthy tissues. Note also that
several OTSCC samples show no evident dysregulation of the
pathway, and they are automatically detected and excluded as
outliers by DEGAS (Figure 4).
Pathways dysregulated in Parkinson’s disease
Parkinson’s disease (PD) is the second most common progressive
neurodegenerative brain disorder in humans, after Alzheimer’s
disease. PD has higher prevalence in males and affects 1 in 100
persons beyond 65 years of age. Pathologically, PD is character-
ized by degeneration of dopaminergic neurons in the substantia
nigra pars compacta (SN), which leads to the depletion of dopamine in
its striatal projections, which in turn leads to disruption of the
cerebral neuronal systems responsible for motor functions [52].
This neurodegeneration is accompanied by the appearance of
cytoplasmic inclusions called Lewy bodies in the surviving neurons
in the SN as well as other regions of the central nervous system
(CNS). The mechanism underlying the formation of these bodies
and their pathological significance are largely unknown. Mutations
in several genes have been linked to PD, but they explain less than
10% of the PD cases, and the mechanism of disease progression is
still largely unknown [53].
We first focused on the PD expression dataset of Moran et al.
[42], as it contained more samples than Lesnick et al. [43]. Using
these expression profiles, we identified a 73-gene pathway as the
most significantly up-regulated pathway in PD (MORAN-PD-UP,
Figure 5). It was strikingly enriched with genes related to
splicing– it contained 15 genes annotated with RNA splicing in
GO ‘‘biological process’’ (p=1.17?10
210, FDR,0.1). The module
was identified for k=30, but similar enrichments were seen in the
Table 1. Gene expression datasets used in this study.
Dataset KEGG pathway Reference GEO accession Number of cases
Number of
controls
AD Alzheimer’s disease (AD) [41] GSE5281 10 13
ASTHMA Asthma [46] GSE4302 42 28
PYLORI Epithelial cell signaling in
Helicobacter pylori infection
- GSE5081 8 8
HD Huntington’s disease (HD) [48] GSE3790 38 32
SUN-GLIOBLASTOMA Pathways in cancer [47] GSE4290 77 23
SUN-ASTROCYTOMA Pathways in cancer [47] GSE4290 26 23
SUN-OLIGODENDROGLIOMA Pathways in cancer [47] GSE4290 50 23
ESTILO-OTSCC Pathways in cancer [44] GSE13601 31 26
YE-OTSCC Pathways in cancer [45] GSE9844 26 12
MORAN-PD Parkinson’s disease (PD) [42] GSE8397 29 18
LESNICK-PD Parkinson’s disease (PD) [43] GSE7621 16 9
SLE Systemic lupus erythematosus (SLE) [49] GSE8650 38 21
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pathway dysregulated for k=10 is highlighted in Figure 5). These
results thus suggest a major up-regulation of the splicing
machinery in PD. The literature contains several additional lines
of evidence that splicing is affected in PD. Several studies found
that the splicing of several of the key genes in PD, a-synuclein,
parkin, synphilin-1, FOSB and RGS9, are affected in diseased
individuals and in mouse models of the disease [54,55,56].
Furthermore, DJ-1, one of the genes mutated in genetic PD, has
been implicated in splicing, through regulation of the splicing of
tyrosine hydroxylase by the protein-associated splicing factor (PSF)
[57]. Mitochondrial damage, a common phenomenon of several
neurodegenerative diseases, including PD, Alzheimer’s disease
(AD) and Amyotrophic lateral sclerosis (ALS), was shown to affect
alternative splicing in neural cells by increasing the relative
abundance of shorter isoforms [58]. Finally, a recent study used
three PD microarray datasets that were not used in our study
[59,60,61] and identified the splicing factor SRRM2 as the only
gene that was dysregulated in PD in all three datasets [62]. The
latter study also identified hundreds of alternative splicing events
in the blood of PD patients. However, we are not aware of any
previous reports on a concerted up-regulation of parts of the
splicing machinery in PD patients.
GO is a powerful tool for annotation of gene functions, but
genes sharing a GO annotation are not always part of the same
transcriptional program. In addition, GO does not contain
information about human disease. In order to test if MORAN-
PD-UP reflects such transcriptional programs, including those
affected in diseased individuals, we utilized the curated gene sets
from MSigDB [12] (Table 2). The most significant enrichment
for an MSigDB term in MORAN-PD-UP was ALZHEIMER_-
DISEASE_UP (p=1.57?10
28), which represents the set of genes
up-regulated in the CA1 region of the hippocampus in individuals
with AD [63]. This finding supports the notion that the pathways
underlying neurodegenerative diseases, and in particular AD and
PD, are similar [64]. The second most significant enrichment was
for cell cycle and cell proliferation (PROLIFERATION_GENES,
p=2.84?10
25). The sub-module of proliferation genes in
MORAN-PD-UP included several key cell cycle regulators such
as p27 (CDKN1B), IGF1R, BCL2 and BCL6. At least four of
these genes are known inhibitors of cell growth (CDKN1B, ING1,
BCL6 and BCL2, annotated with ‘‘negative regulation of cell size’’
in GO). MORAN-PD-UP was also slightly enriched with genes
involved in cell death (taken from GO, p=0.001). The presence of
these genes in MORAN-PD-UP indicate that over-expression of a
network of genes involved in cell death could contribute to the loss
of neurons that characterizes PD. Interestingly, this proliferation-
related sub-module was almost entirely disjoint from the genes
involved in RNA splicing, as only two genes, SMNDC1 and
CROP, were shared between them (Figure 5). This may indicate
that the splicing and the anti-proliferation modules are in fact
separate. However, a recent study has implicated a splicing factor
SRPK2 in neuronal cell death through regulation of cell cycle
progression [65]. Interestingly, this regulation involves the 14-3-3
complex, a subunit of which, YWHAG, is the major hub in
MORAN-PD-UP (see below). SPRK2 does not appear in
Figure 4. A dysregulated pathway in oral tongue squamous cell carcinoma. (A) The subnetwork of YE-OTSCC-UP, up-regulated in patients
with oral tongue small cell carcinoma (OTSCC). Genes annotated with ‘‘cell cycle’’ in GO are in red. Diamond shaped nodes correspond to genes
frequently mutated in cancer (taken from CGP [50]). (B) Expression patterns of the genes in the pathway. The expression pattern of each gene was
normalized to mean 0 and standard deviation of 1. Arrows indicate six outlier samples selected by DEGAS.
doi:10.1371/journal.pone.0013367.g004
Figure 3. Comparison of methods for identifying disease-related pathways. For each dataset, each of the six methods was used to identify
a module up-regulated, down-regulated or differentially expressed in cases compared to controls. The most significant module is shown for each
method and each dataset, except those in which BioNet did not report any module. (A) The significance of the overlap between the obtained module
and the KEGG disease pathway. (B) Comparison of the sizes of the modules. All modules are shown (C) Comparison of the fraction of the module
genes that also appear in the relevant KEGG pathway. Only the most significant module is shown for each dataset and for each method.
doi:10.1371/journal.pone.0013367.g003
DEGAS
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and cell cycle-related genes, as well as a 14-3-3 component in this
network, suggest that the role of up-regulation of splicing
machinery, regulating cell cycle progression and leading to
neuronal death, could be more important than previously
appreciated.
A recent study has found little overlap in the gene lists reported
by different studies of the PD transcriptome [66]. In order to test
the consistency of the results in another dataset, we analyzed
another PD dataset due to Lesnick et al. [43], in which expression
data from 16 PD cases were compared to 9 controls. The most
significant subnetwork (LESNICK-PD-UP) was found for k=25
(p,0.002) (Figure 6). Strikingly, LESNICK-PD-UP indicated the
same enrichments (contained parts of the same pathways) as
MORAN-PD-UP. It was significantly enriched with RNA splicing
(1.42?10
27, FDR,0.1). Consistent with the anti-proliferation
trend identified in MORAN-PD-UP, we also found a slight
enrichment for ‘‘regulation of growth’’ genes in LESNICK-PD-
UP (p=0.006), with two genes known to be negative regulators of
growth – ING1 and BCL6, shared with MORAN-PD-UP.
14-3-3 subunits are hubs in both PD up-regulated
pathways
The main hubs in MORAN-PD-UP and LESNICK-PD-UP
were YWHAB and YWHUG, respectively, the beta and the
gamma polypeptides of the 3-monooxygenase 5-monooxygenase
protein (14-3-3b and 14-3-3c, respectively). In both networks, the
14-3-3 subunits were not significantly altered in most patients, but
their neighborhoods were significantly dysregulated. We note that
the neighborhoods of the two genes are overlapping (103 out of
169 nodes adjacent to YWHAB are also adjacent to YWHAG),
and it is likely that both YWHAB and YWHAG take part in the
same dysregulated pathway. Thus, the subnetworks we identified
in both studies link 14-3-3 subunits to PD. Another 14-3-3 subunit,
14-3-3j, was shown to localize to Lewy bodies and to regulate
parkin, a gene mutated in a subset of the genetic cases of PD
[67,68].
Lewy bodies, a hallmark of PD brain, contain aggregates of a-
synuclein, which has a structural homology to 14-3-3 and binds it.
Furthermore, the 14-3-3 subunit 14-3-3j was shown to localize to
Lewy bodies [69], and 14-3-3 proteins were shown to bind
Figure 5. A DP of genes up-regulated in Parkinson’s disease patients in the Moran et al. data. Nodes that appear also in the DP for k=10
are in blue, the radius of each node is proportional to the number of patients in which it is dysregulated. Triangles are genes involved in mRNA
splicing, diamonds are genes involved in cell proliferation.
doi:10.1371/journal.pone.0013367.g005
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least some of the network neighbors of 14-3-3 subunits that appear
in the MORAN-PD-UP and LESNICK-PD-UP are also unchar-
acterized neighbors of a-synuclein. 14-3-3 also plays a role in
regulation of dopamine biosynthesis through its regulation of
tyrosine hydroxylase [70]. Previous studies have failed to identify
genetic mutations in 14-3-3 subunits [69]. Our results indicate that
the involvement of 14-3-3 in PD could be due to transcriptional
dysregulation of the proteins it interacts with rather than due to
protein integrity or expression levels.
Evidence of stress response in PD up-regulated pathways
LESNICK-PD-UP contained three Hsp70 proteins HSPA1A,
HSPA1B and HSPA1L, as well as additional stress-related genes
HSF1, STIP1, PTGES3 and HSP90AA1. This network was also
enriched for predicted targets of the Hsf1 transcription factor
(p=1.1?10
25, FDR,0.1, taken from MSigDB). HSP1A also
appeared in MORAN-PD-UP, which was also enriched with
predicted Hsf1 targets (p=1.5?10
23, FDR,0.1). Up-regulation of
Hsp-related proteins has also been noted in another study of the
PD substantia nigra transcriptome, the data of which was
unfortunately not available [71]. This up-regulation of the heat-
shock response, observed in multiple studies, is consistent with the
hypothesis that this response is activated as a result of the aberrant
protein folding occurring in PD.
Pathway down-regulated in PD contains hallmarks of the
disease
We also identified significantly down-regulated pathways in
both PD datasets. Since the most significant pathway identified in
the Lesnick et al. study was very small (7 genes), we will focus here
on the pathway identified in the Moran et al. dataset. (p,0.002),
which was identified for k=30 and contained 67 genes (Figure
S2). This pathway contained several hallmarks of PD. It was
enriched with genes from the KEGG PD pathway (p=2.72?10
25,
FDR,0.1), as well as with genes annotated with ‘‘Parkinson’s
disease’’ in Entrez Gene (including GeneRIFs [72],
p=3.58?10
24). In contrast, the up-regulated PD was not enriched
with either of those PD-related gene sets, perhaps as it contains a
novel biological finding. Neither the up-regulated nor the down-
regulated PDs were enriched with genes mutated in genetic PD
(taken from OMIM [73]). Consistent with our findings in
MORAN-PD-UP, we found that the MSigDB curated gene set
most significantly enriched in MORAN-PD-UP contained genes
down-regulated in Alzheimer’s disease (ALZHEIMERS_DISEA-
SE_DN, p=2.28?10
212). Huntington’s disease, another neurode-
generative disease was highly represented in MORAN-PD-
DOWN. The major hub in this pathway is huntingtin (HD),
mutations in which cause this disease. In addition the KEGG
Huntington’s disease pathway was significantly enriched in
MORAN-PD-DOWN (p=3.32?10
26). GO enrichment analysis
also pointed towards common neural functions such as learning
(p=3.86?10
28) and synaptic transmission (p=4.56?10
27). These
suggest that one of the reasons for the down-regulation of at least
some of the genes in MORAN-PD-DOWN could be loss of
neuronal cells, which is known to confound transcriptome studies
of the SN in PD patients [66]. The second major theme in
MORAN-PD-DOWN was oxidative phosphorylation, with five
genes involved in this process (CYC1, UQCRC2, NDUFS1,
NDUFA9, NDUFV2), all of which also appear in the KEGG PD
pathway. Down-regulation of these genes is a well characterized
feature of PD [71].
Discussion
We developed a novel computational technique for network-
based analysis of case-control gene expression data. The method is
aimed at identifying pathways in the interaction network that
exhibit ample evidence of disruption of transcription that is specific
to diseased patients, but without requiring that any gene is
significantly differentially expressed across all the cases. Applica-
tion of the method to a large-scale protein-protein interaction
network and expression data from seven human diseases has
shown its potential in outlining subnetworks with a high relevance
to the mechanisms of pathogenesis. Comparison to extant
techniques for analysis of gene expression data highlights the
advantages of our approach in identifying clinically sound
pathways.
While the results presented here are encouraging, there is
certainly room for further development of these methods, which
can be extended in several directions. First, we currently report
only a single subnetwork for each pathway, whereas clearly, in
some diseases, multiple distinct pathways can be affected. One
possible way of seeking multiple subnetworks is to iteratively find
and remove the most significant DP from the network. Better
methods are needed to detect overlapping DPs. One possible
alternative is to start the search procedure from multiple starting
points simultaneously, thus ‘‘growing’’ in parallel several DPs.
Another fundamental difficulty in identifying protein interaction
subnetworks using expression data is inclusion of genes that are not
significantly affected on the expression level, but are required for
subnetwork connectivity. We have previously coined the term
‘‘back nodes’’ for such nodes (as opposed to ‘‘front nodes’’, whose
expression level shows variation across the profiles) [23]. Since in
most datasets, only a minority of the genes show significant
expression changes, usually there is a large number of possible
back nodes, and choosing the most relevant ones poses a difficult
challenge. This challenge is made more difficult by the scale-free
nature of protein interaction networks, which contain a small
number of hubs with large degrees [74]. These hubs have a much
higher tendency to be included as back nodes. In DEGAS, we
attempt to address this problem by removing from the networks
hubs that are not relevant for the studied dataset (see Methods).
Table 2. MSigDB terms from the ‘‘curated gene sets’’




























Only annotations with FDR,0.1 are shown.
doi:10.1371/journal.pone.0013367.t002
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nodes, while still allowing highly connected proteins to appear in
DPs. We believe there is room for further improvement of this
approach, in order to include only disease-related hubs in the
dysregulated pathways.
Finally, our problem formulation used a fixed k value, thus
requiring that the same lower bound on the genes altered in each
patient. All the algorithms and proofs presented here and in the
Text S1 are generalizable to the scenario where different samples
have different thresholds, but specifying such thresholds remains a
difficult problem open for further investigation.
One of our main goals was to develop a method that will allow
de novo detection of pathways affected by human disease, without
requiring that individual genes in the pathway are differentially
expressed. This approach is motivated by several recent studies
that have shown that human diseases have relatively few genes that
are frequently affected in cases, but that mutations tend to cluster
in specific disease-related pathways [7,8,9,10]. Here we use gene
expression to define gene dysregulation. Naturally, our approach
can be extended to other definitions of dysregulation, in particular
genetic dysregulation by SNPs and copy number changes, which
are now extensively studied on a genome-wide scale. The
challenge in this extension is the distinction between mutations
that disrupt the activity of the gene and ‘‘passenger’’ mutations
that have little effect. Furthermore, it is highly desirable to develop
a method that will be able to detect subnetworks affected at
different levels, including genetic alternations, transcription and
post-transcriptional and post-translational regulation. Measuring
some of the relevant quantities (e. g. protein expression) on a
genome-wide scale will require advancement of experimental
methods beyond what is possible today.
Our analysis of gene expression in the substantia nigra of PD
patients highlights the significant up-regulation of splicing
machinery and negative regulators of cell proliferation. Impor-
tantly, the results we describe here could not be obtained using a
standard statistical approach. At FDR,0.05, 34 genes are found
as up-regulated in the Lesnick et al. study showing no significant
enrichment for RNA splicing (0.046 before correction for multiple
testing). 377 genes are found as up-regulated in the Moran et al.
study and they are significantly enriched for RNA processing, but
show no significant enrichment for cell proliferation. The two sets
obtained using a t-test on both datasets have only 13 genes in
Figure 6. A DP of genes up-regulated in Parkinson’s disease patients in the Lesnick et al. data. Nodes in common with MORAN-PD-UP
are in blue. Triangles are genes involved in RNA splicing (taken from GO). Diamonds are genes involved in regulation of growth (taken from GO).
doi:10.1371/journal.pone.0013367.g006
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regulated in PD in those two datasets was 12.7%, compared to just
5.5% for t-test.
We believe that we have presented here a novel and important
approach for using PPI networks in human case-control gene
expression studies. Numerous confounding factors can make the
discovery of robust disease signatures difficult. Our use of a PPI
network places the dysregulation of each gene in the context of the
dysregulation of its neighbors and allows detection of a pathway
dysregulation signature, which is more robust and more
biologically relevant. As the quality and the extent of both gene
expression datasets and, more importantly, the human PPI
network are expected to vastly improve, we believe that this
approach will be widely adopted.
Methods
Basic graph theoretic definitions
We first define several basic graph theoretic terms. Unless
indicated otherwise, all the terms refer to the input graph
G=(V,E), which represents the protein interaction network. N(v)
is a set of neighbors of v in G. Given two nodes v and u, the distance
between u and v, denoted d(u,v), is the length in edges of a shortest
path between u and v in the graph. The r-neighborhood of a node v is
the set of all the nodes in the graph at distance #r from v. The
radius of a graph is the least r such there exists a node whose r-
neighborhood contains the entire graph. Equivalently, it is the
value minvMVmaxuMV{d(v,u)}. A Breadth First Search (BFS), is a
graph traversal algorithm that starts at a node v1 in the graph and
iteratively scans the graph such that in iteration i it visits the nodes
that are at distance i from v1.ABFS tree is a graph in which each
node is connected to the node in the previous level of the BFS
search that was used to discover it. See [75] for more details.
The Connected Set Cover problem
We formalize the problem of finding DPs as follows. We are
given an undirected graph G=(V,E) and a collection of sets
{Sv}vMV over the universe of elements U, with |U|=n. In our
biological context, U is the set of the cases, and Sv is the set of cases
in which gene v is dysregulated. For ease of representation, we will
use, in addition to G, a bipartite graph B=(V,U,E
B) where for vMV,
uMU( v,u)ME
B if and only if uMSv (Figure 1D). A set C#Vi sa
connected (k,l)-cover (denoted CC(k,l)) if C induces a connected
component in G and a subset U’#U exists such that |U’|=n-l and
for all u’MU’,| N(u’) >C|$k, i.e., in the induced subgraph (C,U’)
(the subgraph in B that contains all the edges of E
B between the
node sets C and U’) the minimal degree of nodes in U’ is at least k.
We are interested in finding a CC(k,l) of the smallest cardinality.
We denote this minimization problem by MCC(k,l).
Similar problems
Given a universe W of n elements and a collection of sets
S1,...,Sm#W, the set cover problem is to identify a smallest collection
of sets such that all the elements are included in their union. If G is
a clique (fully connected), every C#V is connected, and therefore
MCC(1,0) is equivalent to the set cover problem. For this classical
NP-hard problem, Johnson proposed a simple greedy algorithm
with approximation ratio O(ln(n)) [76]. This ratio is the best
possible unless P has slightly super-polynomial time algorithms
[77]. If k.1 and G is a clique, the MCC(k,0) problem is equivalent
to the set multicover problem, also known as the set k-cover problem, a
variant of the set cover problem in which every element has to be
covered k times. The set multicover problem can be approximated
to factor of O(p), where p is the number of sets covering the element
that appears in the largest number of sets [78]. The greedy
algorithm for set multicover was shown to achieve an approxi-
mation ratio of O(log(n)) [79]. See [78] for a comprehensive review
of the available approximation results on set cover and set
multicover problems.
For a general G, MCC(1,0) is the connected set cover problem, which
has been recently studied in the context of wavelength assignment
of broadcast connections in optical networks [80]. It was shown to
be NP-Hard even if at most one vertex of G has degree greater
than two, and approximation algorithms were suggested for the
cases where G is a line graph or a spider graph. Neither of these
special cases is applicable in our biological context.
The Minimal Radius Connected Set Cover problem
An initial analysis using the basic formulation has produced
results that are not always satisfactory from the biological
standpoint (results not shown). We also found that biologically
relevant subgraphs generally tend to have small average shortest
path. As minimizing or constraining the average shortest path of a
graph is difficult, we chose to look for a minimal set that also had a
small radius. In this study we thus aim to solve the minimal radius
minimal connected set cover (MRMCC) problem, which is the following
problem: Let rmin be the minimum value such that there exists
S#V that is a CC(k,l) of radius rmin. Then MRMCC seeks a
minimum cardinality CC(k,l) of radius rmin.
MRMCC(k,l) is equivalent to MCC(k,l) in terms of
computational complexity
We now show that an algorithm solving MCC(k,l) can be
efficiently used to solve MRMCC(k,l). If there exists a CC(k,l) of
radius rmin, it contains a node whose rmin-neighborhood contains a
CC(k,l). Our method will focus on finding such nodes. rmin can be
efficiently found in polynomial time using the following procedure.
We initialize an empty array A with n entries and starting from
every possible root node v, use BFS on G to find all the nodes at
distance i from v for i=1,2,3,…. When each node is reached, the
entries in A corresponding to the elements it covers are
incremented. After all the nodes in a level of BFS have been
scanned, use A to check if at least n-l elements have been covered
at least k times. This condition is met for the first time when i
equals the smallest r for which a CC(k,l) is found in the r-
neighborhood of v. After this procedure is executed for each vMV,
we can identify the value of rmin, and the set Vmin of nodes that
contain a CC(k,l) in their rmin-neighborhood. Clearly, the optimal
solution to MRMCC(k,l) must be contained within the rmin-
neighborhood of one of the nodes in Vmin, and if we solve
MCC(k,l) for each of those rmin-neighborhoods, we will obtain an
optimal solution to MRMCC(k,l). We can thus identify rmin and Vmin
using |V| executions of the BFS algorithm, each taking
O(|V|+|E|). MRMCC(k,l) can thus be reduced to MCC(k,l)i n
polynomial time. Practically, we use the approach described above
to solve MRMCC(k,l)( Figure 2). To speed up the search for Vmin,
after a subset of the nodes has been tested as potential roots, if the
currently smallest radius is rmin*, for all subsequent root nodes, we
halt the BFS procedure when it reaches level rmin*+1.
ExpandingGreedy algorithm for MCC(k,l)
We now describe a heuristic called ExpandingGreedy for
solving MCC(k,l), which is used in DEGAS. This was one of
several algorithms we developed for the problem and it proved
best in practice. The other algorithms for MCC(k,l) and their
comparison are described in the Text S1. ExpandingGreedy is
motivated by the greedy approximation algorithm for the set cover
DEGAS
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the set of corresponding k-covered elements X#U, the algorithm
picks a node vMV that is adjacent to W and that covers the largest
number of elements of U\X and adds v to the cover. In case of a
tie, the nodes are ranked based on the total number of elements
covered by their neighbors, and the best node is selected. Initially
W=Ø, X=Ø and the first node is picked without connectivity
constraints.
Unfortunately, ExpandingGreedy can be shown in some instances
to give a solution that is O(|V|) times the optimal solution for
MCC(1,0) (Text S1, Figure S3). However, augmented with
powerful heuristics, some of which are described below, our
extensive testing shows that it performs better than other
algorithms for MCC(k,l) (Text S1 and Figure S1).
Practical heuristics and implementation details
In order to improve the performance of DEGAS, we
implemented several practical heuristics, which significantly
decrease the size of the obtained DPs (see Text S1).
N ExpandingGreedy*2. Since ExpandingGreedy always se-
lects the node covering the most uncovered elements, the set of
l outliers is not selected until the algorithm halts. Because of
this, ExpandingGreedy may add superfluous nodes covering
elements that will eventually be discarded as outliers. This
problem can be partially addressed by choosing a set of ‘‘good’’
outliers in advance. We therefore used the following heuristic –
we first ran the ExpandingGreedy algorithm and identified the
set of l outliers O#U. We then ran the same algorithm hiding
the nodes in O, and setting l to zero. This heuristic sometimes
significantly reduced the number of nodes in the cover (Figure
S1).
N Hub hiding. One of the key challenges for methods based on
connectivity in PPI networks in mammals is the biased nature
of the known networks, in which heavily studied genes, such as
p53, are highly connected ‘‘hubs’’ in the network. In some
cases this high connectivity has biological meaning, but in
others, it could merely be the result of more extensive testing of
interactions for some genes. This issue requires special
attention, as a simplistic algorithm will include those hubs in
the solution, even if they are not related to the studied disease.
In order to avoid irrelevant yet highly connected nodes, we
introduced a preliminary step in which hubs were removed
from the network, unless the node and genes in its direct
neighborhood (i.e., the network nodes adjacent to the hub)
experienced many dysregulation events. Specifically, we
filtered out nodes with degree .100, for which the average
number of covered elements in their direct neighborhood was
not in the top 25%, compared to all the direct neighborhoods
in the graph.
N Clean-up heuristic. The DPs produced by Expanding-
Greedy may contain superfluous nodes that are necessary
neither for the cover requirements nor for subnetwork
connectivity. We therefore perform a clean-up step that
iteratively removes such nodes, while maintaining network
connectivity, until no further reduction is possible. This step is
applied also to all other algorithms described in the Text S1.
Parameter setting
To select the k value, 200 random networks were generated by
random shuffling of the gene names of the nodes in G. DEGAS
was then executed on each network, for a range of values of k, and
an empirical p-value was computed as the fraction of these 200
networks in which DEGAS found a smaller DP than the one found
in the real network. The k for which the size of the DP was most
significant was subsequently used. In case of a tie, a normal
distribution was fitted to the random scores, and k yielding the
subnetwork with the most significant z-score was selected.
Gene expression data and specification of dysregulated
genes
All gene expression datasets were obtained from GEO [1]. The
original normalization of each dataset was used, and values were
log-transformed if necessary. Probes corresponding to the same
EntrezGene identified were averaged, and genes which did not
appear in the network were discarded. For each gene, the average
and the standard deviation of its expression in the control samples
were computed. These were used to fit a normal distribution and
to compute a p-value for the expression of the gene in each case
sample. The gene was considered differentially expressed if this p-
value was ,0.05 and the ratio between its expression level in the
case sample and the average expression in the controls was at least
1.4.
Human protein interaction network
We compiled a human protein-protein interaction network
encompassing 10,682 nodes corresponding to Entrez Gene
identifiers and 50,185 interactions. The interactions are based
mostly on small-scale experiments and were obtained from several
interaction databases. The network is available at the supplemen-
tary website http://acgt.cs.tau.ac.il/degas. A list of sources used to
create the network and the number of interactions from each
source in the network appears in File S1.
Implementation of other methods
jActiveModules was applied using Cytoscape [81] to the p-
values computed for each case by fitting a normal distribution to
the gene expression levels in the controls. The top scoring module
was selected for further analysis. GiGA was implemented as
described in the original manuscript [31], and the module size was
set to equal the module size identified by DEGAS. The method of
Dittrich et al. [32] was applied using its implementation in the
BioNet R package. The runFastHeinz heuristic was used with the
FDR set to 0.01.
Implementation details
A JAVA implementation of DEGAS is integrated into the
MATISSE software package alongside implementations of other
algorithms combining network and gene expression data
[22,23,82]. This implementation allows the user to set all the
parameters described in this paper, to execute the different
algorithms described here and in the Text S1 and dynamically
view the resulting dysregulated pathways.
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Text S1 Supplementary Methods
Found at: doi:10.1371/journal.pone.0013367.s001 (0.06 MB
DOC)
Figure S1 Comparison of cover sizes found by different
algorithms for MCC(k,l). Each dataset is represented by three
rows corresponding to identifying DPs up-regulated, down-
regulated or differentially expressed. For each dataset and each
dysregulation direction, we ranked the cover sizes obtained by
each algorithm according to their size. The smallest cover was
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Figure S2 A DP of genes down-regulated in Parkinson’s disease
patients in the Moran et al. data. Nodes annotated with
transmission of nerve pulse in GO are in blue. Triangles are
genes that appear in the Parkinson’s disease pathway in KEGG.
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Figure S3 A worst case scenario for the performance of
ExpandingGreedy for MCC(1,0).
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